You are here

  • Home
  • Archive
  • Volume 69, Issue 11
  • Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry

Article Text

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry
  1. Bente Glintborg1,
  2. Mikkel Østergaard2,
  3. Niels Steen Krogh3,
  4. Lene Dreyer4,
  5. Hanne Lene Kristensen5,
  6. Merete Lund Hetland2,6
  1. 1Department of Rheumatology, Gentofte University Hospital, Hellerup, Denmark
  2. 2Department of Rheumatology, Copenhagen University Hospitals at Hvidovre and Glostrup, Denmark
  3. 3Zitelab Aps, Copenhagen, Denmark
  4. 4Department of Rheumatology, Rigshospitalet, Copenhagen, Denmark
  5. 5Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark
  6. 6The Danish Rheumatological Database (DANBIO), Hvidovre, Denmark
  1. Correspondence to Mrs Bente Glintborg, Gentofte University Hospital, Niels Andersensvej 65, 2900, Hellerup, Denmark; glintborg{at}dadlnet.dk

Abstract

Objectives To use prospectively registered data from the Danish nationwide rheumatological database (DANBIO) to describe disease activity, clinical response, treatment duration and predictors of drug survival (ie, number of days individual patients maintained treatment) and clinical response among patients with ankylosing spondylitis (AS) receiving their first treatment series with a tumour necrosis factor α (TNFα) inhibitor.

Methods 842 TNFα inhibitor naive patients with AS were identified in DANBIO. Clinical response, drug survival and predictors thereof were investigated. ‘Clinical response’ was defined as a 50% or 20 mm reduction in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) within 6 months compared with baseline. Achievement of a BASDAI <40 mm within 6 months was used as a second response parameter.

Results 603 patients (72%) were men, disease duration 5 (1–13) years (median (IQR), age 41 (32–50) years. 445 (53%) received infliximab, 247 (29%) adalimumab and 150 (18%) etanercept. Parameters at baseline/1-year follow-up were: C-reactive protein (CRP): 14 (7–27)/5 (2–10) mg/l, BASDAI 59 (44–72)/21 (8–39) mm, Bath Ankylosing Spondylitis Functional Index (BASFI) 50 (34–67)/24 (9–45) mm, Bath Ankylosing Spondylitis Metrology Index 40 (20–50)/20 (10–40) mm. Within 6 months, 407/644 patients (63%) achieved a clinical response. Median drug survival was 4.3 years. One- and 2-year survival rates were 74% and 63%, respectively. Baseline characteristics associated with longer drug survival were male gender, CRP >14 mg/l and low visual analogue scale fatigue (Cox regression analysis). Age, TNFα inhibitor and methotrexate use were insignificant. CRP >14 mg/l, lower BASFI and younger age at baseline was associated with clinical response and achievement of a BASDAI <40 mm (logistic regression analysis).

Conclusion TNFα inhibitors provide a rapid and sustained decrease of disease activity among patients with AS in clinical practice. Factors associated with continued treatment, clinical response and achievement of a BASDAI <40 mm were identified.

https://doi.org/10.1136/ard.2009.124446

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests MLH has received consulting fees, speaking fees and/or research grants from Abbott, Centocor, Roche, Schering-Plough, UCB-Nordic and Wyeth (less than US$10 000 each), and on behalf of DANBIO, she has received grants from Abbott, Bristol-Meyers Squibb, Roche, Schering-Plough, UCB-Nordic and Wyeth (more than US$10 000 each). MO has received consulting fees, speaking fees and/or research grants from Abbott, Amgen, Bristol-Meyers Squibb, Centocor, Genmab, GlaxoSmithKline, Novo, Pfizer, Roche, Schering-Plough, UCB-Nordic and Wyeth (less than US$10 000 each).

    • Provenance and peer review Not commissioned; externally peer reviewed.